Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study

HC Chung; YJ Bang; J Tabernero; E Van Cutsem; CS Fuchs; L Wyrwicz; KW Lee; I Kudaba; M Garrido; H Castro; W Mansoor; MI Braghiroli; E Goekkurt; J Chao; ZA Wainberg; U Kher; S Shah; K Shitara

Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study

HC Chung, YJ Bang, J Tabernero, E Van Cutsem, CS Fuchs, L Wyrwicz, KW Lee, I Kudaba, M Garrido, H Castro, W Mansoor, MI Braghiroli, E Goekkurt, J Chao, ZA Wainberg, U Kher, S Shah, K Shitara

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	125O
Pages (from-to)	IX43-IX44
Journal	Annals of Oncology
Volume	30
Issue number	Suppl.9
Publication status	Published - Nov 2019
Externally published	Yes
Event	European Society for Medical Oncology (ESMO) Asia Congress - Singapore, Singapore Duration: 22 Nov 2019 → 24 Nov 2019 https://oncologypro.esmo.org/meeting-resources/esmo-asia-congress-2019

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

https://www.annalsofoncology.org/article/S0923-7534(19)57802-4/fulltext

Cite this

Chung, HC., Bang, YJ., Tabernero, J., Van Cutsem, E., Fuchs, CS., Wyrwicz, L., Lee, KW., Kudaba, I., Garrido, M., Castro, H., Mansoor, W., Braghiroli, MI., Goekkurt, E., Chao, J., Wainberg, ZA., Kher, U., Shah, S., & Shitara, K. (2019). Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study. Annals of Oncology, 30(Suppl.9), IX43-IX44. Article 125O. https://www.annalsofoncology.org/article/S0923-7534(19)57802-4/fulltext

@article{ce017b267e7b4181a14e727dc58ec4eb,

title = "Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study",

author = "HC Chung and YJ Bang and J Tabernero and {Van Cutsem}, E and CS Fuchs and L Wyrwicz and KW Lee and I Kudaba and M Garrido and H Castro and W Mansoor and MI Braghiroli and E Goekkurt and J Chao and ZA Wainberg and U Kher and S Shah and K Shitara",

year = "2019",

month = nov,

language = "English",

volume = "30",

pages = "IX43--IX44",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "Suppl.9",

note = "European Society for Medical Oncology (ESMO) Asia Congress, ESMO ; Conference date: 22-11-2019 Through 24-11-2019",

url = "https://oncologypro.esmo.org/meeting-resources/esmo-asia-congress-2019",

}

Chung, HC, Bang, YJ, Tabernero, J, Van Cutsem, E, Fuchs, CS, Wyrwicz, L, Lee, KW, Kudaba, I, Garrido, M, Castro, H, Mansoor, W, Braghiroli, MI, Goekkurt, E, Chao, J, Wainberg, ZA, Kher, U, Shah, S & Shitara, K 2019, 'Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study', Annals of Oncology, vol. 30, no. Suppl.9, 125O, pp. IX43-IX44. <https://www.annalsofoncology.org/article/S0923-7534(19)57802-4/fulltext>

TY - JOUR

T1 - Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC)

T2 - European Society for Medical Oncology (ESMO) Asia Congress

AU - Chung, HC

AU - Bang, YJ

AU - Tabernero, J

AU - Van Cutsem, E

AU - Fuchs, CS

AU - Wyrwicz, L

AU - Lee, KW

AU - Kudaba, I

AU - Garrido, M

AU - Castro, H

AU - Mansoor, W

AU - Braghiroli, MI

AU - Goekkurt, E

AU - Chao, J

AU - Wainberg, ZA

AU - Kher, U

AU - Shah, S

AU - Shitara, K

PY - 2019/11

Y1 - 2019/11

UR - https://www.webofscience.com/wos/alldb/full-record/WOS:000503487700122

M3 - Meeting Abstract

SN - 0923-7534

VL - 30

SP - IX43-IX44

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl.9

M1 - 125O

Y2 - 22 November 2019 through 24 November 2019

ER -

Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this